CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-22-1029
Abstract: SIGNIFICANCE CD137 (4-1BB) is a costimulatory receptor of T and natural killer lymphocytes whose activity can be exploited in cancer immunotherapy strategies as discovered 25 years ago. Following initial attempts that met unacceptable toxicity, new… read more here.
Keywords: cd137 1bb; cancer; 1bb based; cancer immunotherapy ... See more keywords